贝伐珠单抗联合以氟尿嘧啶为基础的化疗方案治疗晚期结直肠癌的临床研究  

Bevacizumab combined with fluorouracil-based chemotherapy protocol for advanced colorectal cancer

作　　者：李永冰 Li Yongbing(Department of Gastroenterology,Xuchang People’s Hospital,Xuchang 461000,China)

机构地区：[1]许昌市人民医院消化内科,许昌461000

出　　处：《中国实用医刊》2025年第2期89-92,共4页Chinese Journal of Practical Medicine

摘　　要：目的研究贝伐珠单抗联合以氟尿嘧啶为基础的化疗方案治疗晚期结直肠癌(CRC)的临床效果。方法队列研究。抽取2020年1月至2022年12月许昌市人民医院收治的晚期CRC患者78例,按随机数字表法分为贝伐珠单抗组和氟尿嘧啶组,每组39例。氟尿嘧啶组采用以氟尿嘧啶为基础的化疗方案(氟尿嘧啶^(+)奥沙利铂),贝伐珠单抗组在氟尿嘧啶组基础上采用贝伐珠单抗。比较两组疗效,比较两组治疗前后肿瘤标志物[糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平、免疫功能[T淋巴细胞(CD3^(+)、CD4^(+)、CD8^(+))],比较两组不良反应发生率。结果贝伐珠单抗组总有效率(74.35%,29/39)高于氟尿嘧啶组(51.28%,20/39),P<0.05。治疗后,贝伐珠单抗组CA19-9、CA125、CEA水平低于氟尿嘧啶组(P<0.05);治疗后,贝伐珠单抗组CD3^(+)、CD4^(+)水平高于氟尿嘧啶组,CD8^(+)水平低于氟尿嘧啶组(P<0.05)。两组食欲减退、白细胞减少、恶心呕吐、骨髓抑制、乏力发生率比较差异未见统计学意义(P>0.05)。结论贝伐珠单抗联合以氟尿嘧啶为基础的化疗方案应用于晚期CRC治疗中,可提高治疗的有效率,降低肿瘤标志物水平,改善患者免疫功能,且不会增加不良反应发生率。Objective To study the clinical effect of bevacizumab combined with fluorouracil-based chemotherapy protocol on advanced colorectal cancer(CRC).Methods A total of 78 patients with advanced CRC treated in Xuchang People’s Hospital from January 2020 to December 2022 were selected for the cohort study.And they were divided into the bevacizumab group and the fluorouracil group using a random number table method,with 39 cases in each group.The fluorouracil group received fluorouracil-based chemotherapy protocol(fluorouracil^(+)oxaliplatin),and the bevacizumab group received bevacizumab based on the treatment of the fluorouracil group.The therapeutic effects,levels of tumor markers including carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA),immune function evaluated by T lymphocytes including cluster of differentiation 3^(+)(CD3^(+)),cluster of differentiation 4^(+)(CD4^(+))and cluster of differentiation 8^(+)(CD8^(+)),and incidence of adverse reactions were compared between the two groups.ResultsThe total effective rate of the bevacizumab group(74.35%,29/39)was higher than that of the fluorouracil group(51.28%,20/39),P<0.05.After treatment,the levels of CA19-9,CA125,and CEA in the bevacizumab group were lower than those in the fluorouracil group(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in the bevacizumab group were higher than those in the fluorouracil group,and the level of CD8^(+)was lower than that in the fluorouracil group(P<0.05).There was no significant difference in the incidences of anorexia,leukopenia,nausea-vomiting,bone marrow suppression and fatigue between the two groups(P>0.05).Conclusions The application of bevacizumab combined with fluorouracil-based chemotherapy in the treatment of advanced CRC can improve effectiveness of treatment,reduce levels of tumor markers,improve immune function,and does not increase the incidence of adverse reactions.

关 键 词：结直肠癌 晚期 贝伐珠单抗 氟尿嘧啶 

分 类 号：R73[医药卫生—肿瘤]